27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
CTI BioPharma Corp. (NASDAQ: CTIC) shares are trading higher on Monday after the company announced its preliminary results of PERSIST-2 that met one of the co-primary endpoints in phase three study.
Earlier, in the day, the company disclosed top line results of a randomized, controlled final stage clinical study of PERSIST-2 comparing pacritinib for the treatment of patients with myelofibrosis. A total of 311 patients were enrolled in the trial that formed the basis for the safety analysis.
The company indicated that the end point demonstrated statistically significant response rate in spleen volume reduction (SVR) in patients, who get treatment for myelofibrosis. Though its PERSIST-2 study failed to meet the other co-primary endpoint, its preliminary analysis approached marginal significance in comparison with BAT.
CTI BioPharma President and CEO, James Bianco, said, "Having analyzed data from two Phase 3 trials with the only JAK inhibitor to be studied in severely thrombocytopenic patients, including patients on JAK2 therapy or those who failed prior JAK2, we are encouraged by pacritinib's clinical profile in this difficult-to-treat group of patients with myelofibrosis."
At time of writing, the stock traded up by $0.044, or 12.66 percent, to $0.394.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!